[
  {
    "ts": "2026-01-08T01:15:48+00:00",
    "headline": "Is It Time To Reassess Quest Diagnostics (DGX) After Recent Share Price Strength?",
    "summary": "If you are wondering whether Quest Diagnostics shares still offer good value at around US$178.14, the key question is how that price compares with what the business might reasonably be worth. The stock has returned 2.7% over the last week and 2.5% year to date, with a 17.8% return over the past year and 56.6% over five years. These figures may affect how you think about potential upside or downside from here. Recent attention on Quest Diagnostics has centered on its role as a major medical...",
    "url": "https://finance.yahoo.com/news/time-reassess-quest-diagnostics-dgx-011548656.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "747bc44e-5f90-3f47-bf47-0a3e522c84e2",
      "content": {
        "id": "747bc44e-5f90-3f47-bf47-0a3e522c84e2",
        "contentType": "STORY",
        "title": "Is It Time To Reassess Quest Diagnostics (DGX) After Recent Share Price Strength?",
        "description": "",
        "summary": "If you are wondering whether Quest Diagnostics shares still offer good value at around US$178.14, the key question is how that price compares with what the business might reasonably be worth. The stock has returned 2.7% over the last week and 2.5% year to date, with a 17.8% return over the past year and 56.6% over five years. These figures may affect how you think about potential upside or downside from here. Recent attention on Quest Diagnostics has centered on its role as a major medical...",
        "pubDate": "2026-01-08T01:15:48Z",
        "displayTime": "2026-01-08T01:15:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5bcfe52095f73041f79c669b593d7118",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pUPV1p_Bw8ydOCyP5dgMaw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bcfe52095f73041f79c669b593d7118.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SLvgYYeIn3Dw6STv9CZZCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5bcfe52095f73041f79c669b593d7118.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/time-reassess-quest-diagnostics-dgx-011548656.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/time-reassess-quest-diagnostics-dgx-011548656.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DGX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]